It can directly act on the inflamed mucosa and has anti-inflammatory effects. Animal experiments show that it can effectively inhibit ulcers caused by aspirin. This compound preparation can inhibit the production of pepsinogen in the gastric mucosa of rats.

It promotes the biochemical synthesis of hexosamine and glucosamine, the components of gastrointestinal mucosal epithelium, protects and repairs gastrointestinal mucosal damage, and can inhibit ulcers caused by aspirin and indomethacin in experiments with pyloric ligation in rats. This compound preparation promotes the healing of experimental ulcers in various rats, suggesting that it has a therapeutic effect on low-acid (acid-free) ulcers.

No specific description provided

Extract from the above information

Improve the sensitivity of liver and peripheral tissues to insulin, improve glucose uptake and utilization. It may also have the effect of improving blood lipid levels and fibrinolytic protein activity.

It can stimulate pancreatic β cells to secrete insulin. Its mechanism of action is to specifically bind to the sulfonylurea receptors on the β cell membrane, thereby closing the potassium ion channel and causing a change in membrane potential. As a result, the calcium ion channel opens, and the calcium ions in the cytosol increase, prompting the secretion of insulin. It also has an extrapancreatic effect, which can reduce the liver's insulin resistance to peripheral tissues (muscle, fat). In addition, gliclazide can also reduce platelet adhesion and aggregation, and has fibrinolytic activity.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.